NovaBridge Biosciences (NBP) Operating Leases (2019 - 2025)

NovaBridge Biosciences (NBP) has 7 years of Operating Leases data on file, last reported at $2.2 million in Q4 2025.

• Operating Leases for Q4 2025 came in at $2.2 million, down 29.03% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.2 million (down 29.03% YoY), and the FY2025 annual result was $2.2 million, down 29.03% from the prior year.
• Operating Leases eased to $2.2 million in Q4 2025 per NBP's latest filing, from $2.4 million in the prior quarter.
• Over five years, Operating Leases peaked at $12.8 billion in Q4 2021 and troughed at -$2.6 million in Q2 2022.
• A 5-year average of $986.5 million and a median of $3.0 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2021 and 2022: Operating Leases soared 1529598.65% in 2021, then sank 153.56% in 2022.
• A 5-year view of Operating Leases shows it stood at $12.8 billion in 2021, then tumbled by 99.96% to $4.5 million in 2022, then dropped by 28.85% to $3.2 million in 2023, then dropped by 4.43% to $3.1 million in 2024, then declined by 29.03% to $2.2 million in 2025.
• Business Quant data shows NBP's Operating Leases at $2.2 million in Q4 2025, $2.4 million in Q3 2025, and $2.6 million in Q2 2025.